Veklury - Beechwood Capital

Veklury remdesivir APPROVED

Drug Profile

ModalitySmall molecule

RouteIV

Therapy AreaInfectious Disease

Launch2020-10-22

US LOE2035-10-22

Peak Sales Est$5500M

Formulations[{"id":"veklury-iv","route":"IV","setting":"INPATIENT","frequency":"5-day course","is_primary":true}

Companies

GILD (ORIGINATOR)100%

Mechanism: RNA polymerase inhibitor

Expert: Adenosine nucleotide analog prodrug that inhibits viral RNA-dependent RNA polymerase.

Everyday: Blocks viral replication machinery.

Targets: ["HCV NS5B"]

Revenue History

Programs (1)

Indication	Stage	Key Study	Regional Status
COVID-19 hospitalized	APPROVED	ACTT-1	[{"stage":"APPROVED","region":"US","approval_date":"2020-10-22"}]

Notes

COVID-19 treatment. Revenue declining with lower hospitalization rates.

Data from Supabase · Updated 2026-03-24